IRulya Therapeutics Inc. (IRLA): who owns it and who trades it
As of Nov 16, 2026, IRLA insiders reported 1 open-market sale worth $174K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Luca Benatti (Director), with $174K.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, IRLA insiders reported $0 of open-market purchases and $174K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 26, 2025 | Luca Benatti | Director | Sale | 50,000 | $3.47 | $174K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Luca Benatti | Director | – | $174K | Dec 26, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IRLA short interest
High short interest. 12.6% of IRLA shares are sold short: about 1 share in 8.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 127,816 IRLA shares were sold short, 12.6% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 112,687 shares, buying them all back would take about 1.1 trading days (days to cover).
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 127,816 | 12.57% | -17% | 112,687 | 1.1 |
| Oct 15, 2026 | 154,736 | 15.21% | +158% | 46,846 | 3.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
IRulya Therapeutics company events
IRulya Therapeutics filed 25 reports on Form 8-K in the last 12 months, 11 of them about an important change (leadership, listing). The latest was on Oct 19, 2026.
- Oct 19, 2026AnnouncementShared information with investors. Filing
- Oct 9, 2026LeadershipResignation of Officers As previously announced, effective as of October 8, 2026, Dirk Thye, M.D., resigned as Chief Executive Officer and Chief Medical Officer, as well as a director, of Quince Therapeutics, Inc., which will be renamed IRulya Therapeutics Inc. effective at 4:01 p.m., Eastern Time… Filing
- Oct 6, 2026LeadershipQuince Therapeutics, Inc., held a special meeting of stockholders. Filing
- Oct 2, 2026LeadershipEach of June Bray, David Lamond and Christopher Senner tendered conditional resignations from the Board of Directors of Quince Therapeutics, Inc., in each case effective as of two business days following the conclusion of the Company’s Special Meeting of Stockholders, which will be held on October… Filing
- Sep 14, 2026LeadershipAs previously disclosed, the Company and Charles Ryan, the Company’s President, previously agreed that Mr. Ryan’s last day of employment with the Company would be September 8, 2026. Filing
- Sep 4, 2026ListingQuince Therapeutics, Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s stockholders’ equity was ($35.32… Filing
- Aug 27, 2026LeadershipQuince Therapeutics, Inc. and Charles Ryan, the Company’s President, determined that Mr. Ryan’s last day of employment will be September 8, 2026. Filing
- Aug 17, 2026AnnouncementQuince Therapeutics, Inc. is planning to hold a special meeting of stockholders, at which stockholders will be asked to approve, among other things, (i) the issuance of shares of the Company’s common stock, par value $0.001 per share, upon conversion of the Company’s Series C Non-Voting Convertible… Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Jul 31, 2026LeadershipEach of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc., and a member of the Company’s board of directors, and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations… Filing
- Jul 30, 2026AnnouncementAmended an earlier report. The information set forth in the “Business Section of the Company” reflecting the business of the Company following the acquisition of Orphai is attached hereto as Exhibit 99.4 and incorporated herein by reference. Filing
- Jun 26, 2026SharesAmended an earlier report. Changed the rights of its shareholders. Filing
- Jun 26, 2026SharesChanged the rights of its shareholders. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 21, 2026AnnouncementAs previously disclosed, on March 17, 2026, Quince Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC that the Company had failed to maintain a minimum market value of listed securities of $50 million over the previous 30… Filing
- May 18, 2026AnnouncementAmended an earlier report. Shared information with investors. Filing
- May 18, 2026LeadershipAppointment of Directors In accordance with the Merger Agreement, on May 18, 2026, effective immediately after the Effective Time, Brigette Roberts, M.D., was appointed to the Board as a Class III director. Filing
- Apr 28, 2026AnnouncementQuince Therapeutics, Inc., received a letter from the Nadsaq Listing Qualifications department of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). Filing
- Apr 22, 2026LeadershipThe Board of Directors of Quince Therapeutics, Inc. increased the number of directors on the Board to four and appointed June Bray as a Class I director of the Company to fill the resulting vacancy, effective immediately, to serve until the 2026 Annual Meeting of Stockholders, or until her earlier… Filing
- Apr 9, 2026SharesChanged the rights of its shareholders. Filing
- Mar 30, 2026AgreementEnded an important agreement. Filing
- Mar 20, 2026ListingQuince Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued… Filing
- Feb 12, 2026AnnouncementWe engaged LifeSci Capital as our exclusive financial advisor to assist in restructuring activities and an evaluation of strategic alternatives aimed at maximizing shareholder value. Filing
- Feb 2, 2026LeadershipEach of Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray tendered his or her resignation as a member of the Board of Directors of Quince Therapeutics, Inc., effective as of January 30, 2026. Filing
- Jan 29, 2026AnnouncementMade another announcement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
IRulya Therapeutics financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named IRLA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 10.0% |
| Nov 16, 2026 | SilverArc Capital Management, LLC | 13G/A | 7.9% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 10.0% |
| Nov 16, 2026 | Ikarian Capital, LLC | 13G/A | 2.3% |
| Nov 16, 2026 | Squadron Master Fund LP | 13G/A | 8.8% |
| Nov 16, 2026 | Ikarian Capital, LLC | 13G/A | 2.3% |
| Nov 16, 2026 | SilverArc Capital Management, LLC | 13G/A | 7.9% |
| Nov 16, 2026 | Squadron Master Fund LP | 13G/A | 8.8% |
| Nov 13, 2026 | SilverArc Capital Management, LLC | 13G | 7.9% |
| Nov 13, 2026 | SilverArc Capital Management, LLC | 13G | 7.9% |
| Oct 14, 2026 | Foresite Capital Fund VI LP | 13G | 4.5% |
| Oct 14, 2026 | Foresite Capital Fund VI LP | 13G | 4.5% |
| Oct 14, 2026 | Perceptive Advisors LLC | 13G | 8.4% |
| Oct 14, 2026 | Perceptive Advisors LLC | 13G | 8.4% |
Questions about IRulya Therapeutics Inc. (IRLA) stock
Are IRLA insiders buying or selling?
In the last 12 months, IRLA insiders reported no open-market purchases and 1 sale worth $174K. The latest trade was on Dec 26, 2025. See every trade.
What is the short interest in IRLA?
As of Oct 30, 2026, 127,816 IRLA shares were sold short, 12.6% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 112,687 shares, buying them all back would take about 1.1 trading days (days to cover). See the history.
Executive pay
IRulya Therapeutics's chief executive was paid a total of $2.4M for the year ended Dec 31, 2025, down 12% from $2.7M the year before. In the last 12 months, IRulya Therapeutics's executives and directors bought no stock on the open market and sold $174K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.